Skip to main content
Biogen10-Q: Acquisition completed

Completed acquisition of Apellis Pharmaceuticals on May 14, 2026, for approximately $5.3 billion

Source: Autobound Signal API · 74 signals tracked for Biogen · updated

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.

What happened

Biogen completed the acquisition of Apellis on May 14, 2026, for $41.00 per share in cash totaling approximately $5.3 billion, adding SYFOVRE and EMPAVELI.

Source

SEC EDGARJul 29, 2026

Quarterly report (Form 10-Q)

Biogen 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

On May 14, 2026, we completed the acquisition of all of the issued and outstanding shares of Apellis, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.

sec.gov/Archives/edgar/data/875045/000087504526000075/biib-20260630.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Acquisition completed

What this signalsIntegration work after a deal often opens needs for new systems and services.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Jul 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$5.3B (cash consideration for acquisition of Apellis)

Details

CIK
875045
Accession number
0000875045-26-000075
Timeframe
Current quarter
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
Active integration needs
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
95%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
acquisitionCompleted

Use this data

Get every 10-Q signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/a48f79bd-844c-46d5-a8c9-504f77c496ea returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "a48f79bd-844c-46d5-a8c9-504f77c496ea",
  "signal_type": "sec-10q",
  "signal_subtype": "acquisitionCompleted",
  "detected_at": "2026-11-09T06:30:46.378+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "detail": "Biogen completed the acquisition of Apellis on May 14, 2026, for $41.00 per share in cash totaling approximately $5.3 billion, adding SYFOVRE and EMPAVELI. This integration may create opportunities for post-merger integration services, commercialization tooling, and clinical operations systems.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "cash consideration for acquisition of Apellis",
      "dollar_millions": 5300
    },
    "quarter": "Q2",
    "summary": "Completed acquisition of Apellis Pharmaceuticals on May 14, 2026, for approximately $5.3 billion",
    "excerpts": "On May 14, 2026, we completed the acquisition of all of the issued and outstanding shares of Apellis, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.",
    "relevance": 0.95,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000075/biib-20260630.htm",
    "filing_date": "2026-07-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "Active integration needs",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.